S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
Log in

NASDAQ:GBT - Global Blood Therapeutics Stock Price, Forecast & News

$71.35
+0.19 (+0.27 %)
(As of 02/19/2020 04:00 PM ET)
Today's Range
$70.72
Now: $71.35
$72.79
50-Day Range
$65.26
MA: $75.74
$87.16
52-Week Range
$44.17
Now: $71.35
$87.54
Volume374,004 shs
Average Volume847,382 shs
Market Capitalization$4.30 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.79
Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GBT
CUSIPN/A
Phone650-741-7700

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$10.97 per share

Profitability

Net Income$-174,190,000.00

Miscellaneous

Employees171
Market Cap$4.30 billion
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive GBT News and Ratings via Email

Sign-up to receive the latest news and ratings for GBT and its competitors with MarketBeat's FREE daily newsletter.


Global Blood Therapeutics (NASDAQ:GBT) Frequently Asked Questions

What is Global Blood Therapeutics' stock symbol?

Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."

How were Global Blood Therapeutics' earnings last quarter?

Global Blood Therapeutics Inc (NASDAQ:GBT) announced its quarterly earnings data on Wednesday, August, 7th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.96) by $0.05. During the same quarter last year, the business posted ($0.78) EPS. View Global Blood Therapeutics' Earnings History.

When is Global Blood Therapeutics' next earnings date?

Global Blood Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Global Blood Therapeutics.

What price target have analysts set for GBT?

16 Wall Street analysts have issued 1-year target prices for Global Blood Therapeutics' shares. Their forecasts range from $50.00 to $150.00. On average, they expect Global Blood Therapeutics' stock price to reach $95.60 in the next year. This suggests a possible upside of 34.0% from the stock's current price. View Analyst Price Targets for Global Blood Therapeutics.

What is the consensus analysts' recommendation for Global Blood Therapeutics?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Global Blood Therapeutics in the last year. There are currently 5 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Global Blood Therapeutics.

What are Wall Street analysts saying about Global Blood Therapeutics stock?

Here are some recent quotes from research analysts about Global Blood Therapeutics stock:
  • 1. HC Wainwright analysts commented, "Our Buy rating and $150 PT are based on a DCF analysis, derived using a beta of 1.58, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 9.8%, and tax rate of 15% beginning in FY 2024. We estimate approximately 70K patients in U.S., 42K patients in the $60K U.S. and EU launch prices, respectively, a 2020 commercial launch, 70% compliance, and 23% gross-to-net. In 2022, we model global sales at roughly $820M and expect voxelotor peak sales of $2.7B during 2026, which assumes about 49% adoption across the developed nations, and a POS of 75%." (8/8/2019)
  • 2. According to Zacks Investment Research, "Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California. " (3/4/2019)

Has Global Blood Therapeutics been receiving favorable news coverage?

Media coverage about GBT stock has trended neutral recently, according to InfoTrie. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Global Blood Therapeutics earned a coverage optimism score of 0.5 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Global Blood Therapeutics.

Who are some of Global Blood Therapeutics' key competitors?

What other stocks do shareholders of Global Blood Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Global Blood Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Cynosure (CYNO), Exelixis (EXEL), TherapeuticsMD (TXMD), AbbVie (ABBV), Amarin (AMRN), Roku (ROKU) and Intercept Pharmaceuticals (ICPT).

Who are Global Blood Therapeutics' key executives?

Global Blood Therapeutics' management team includes the folowing people:
  • Dr. Ted W. Love, Pres, CEO & Director (Age 60)
  • Dr. Charles J. Homcy, Founder, Advisor & Director (Age 71)
  • Mr. Jeffrey S. Farrow, Chief Financial Officer (Age 57)
  • Mr. Peter Radovich, Sr. VP of Operations (Age 41)
  • Dr. Hing Sham, Sr. VP of Research (Age 67)

When did Global Blood Therapeutics IPO?

(GBT) raised $102 million in an initial public offering on Wednesday, August 12th 2015. The company issued 6,000,000 shares at $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

Who are Global Blood Therapeutics' major shareholders?

Global Blood Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (9.74%), Perceptive Advisors LLC (9.74%), FMR LLC (8.69%), Bank of America Corp DE (7.82%), Janus Henderson Group PLC (4.98%) and State Street Corp (3.58%). Company insiders that own Global Blood Therapeutics stock include De Dominicis Robert, Deval L Patrick, Joshua Lehrer-Graiwer, Jung Choi, Lesley Ann Calhoun, Philip A Pizzo, Ted W Love and Tricia Borga Suvari. View Institutional Ownership Trends for Global Blood Therapeutics.

Which major investors are selling Global Blood Therapeutics stock?

GBT stock was sold by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, FMR LLC, Franklin Resources Inc., Bank of New York Mellon Corp, State Street Corp, Fernwood Investment Management LLC, Rafferty Asset Management LLC and Sectoral Asset Management Inc. Company insiders that have sold Global Blood Therapeutics company stock in the last year include Deval L Patrick, Joshua Lehrer-Graiwer, Lesley Ann Calhoun, Philip A Pizzo, Ted W Love and Tricia Borga Suvari. View Insider Buying and Selling for Global Blood Therapeutics.

Which major investors are buying Global Blood Therapeutics stock?

GBT stock was acquired by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Janus Henderson Group PLC, Driehaus Capital Management LLC, CIBC Private Wealth Group LLC, Capital World Investors, Crawford Lake Capital Management LLC, Pictet Asset Management Ltd. and California Public Employees Retirement System. View Insider Buying and Selling for Global Blood Therapeutics.

How do I buy shares of Global Blood Therapeutics?

Shares of GBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Global Blood Therapeutics' stock price today?

One share of GBT stock can currently be purchased for approximately $71.35.

How big of a company is Global Blood Therapeutics?

Global Blood Therapeutics has a market capitalization of $4.30 billion. The company earns $-174,190,000.00 in net income (profit) each year or ($3.41) on an earnings per share basis. Global Blood Therapeutics employs 171 workers across the globe.View Additional Information About Global Blood Therapeutics.

What is Global Blood Therapeutics' official website?

The official website for Global Blood Therapeutics is http://www.gbt.com/.

How can I contact Global Blood Therapeutics?

Global Blood Therapeutics' mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-741-7700 or via email at [email protected]


MarketBeat Community Rating for Global Blood Therapeutics (NASDAQ GBT)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  506 (Vote Outperform)
Underperform Votes:  317 (Vote Underperform)
Total Votes:  823
MarketBeat's community ratings are surveys of what our community members think about Global Blood Therapeutics and other stocks. Vote "Outperform" if you believe GBT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GBT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Featured Article: Correction

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel